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HDAC inhibitors (HDACis) have been developed as promising anticancer agents in recent years. In this study, we synthesized and
characterized a novel HDACi, termed NBM-HD-1. This agent was derived from the semisynthesis of propolin G, isolated from
Taiwanese green propolis (TGP), and was shown to be a potent suppressor of tumor cell growth in human breast cancer cells
(MCF-7 and MDA-MB-231) and rat glioma cells (C6), with an IC50 ranging from 8.5 to 10.3μM. Western blot demonstrated that
levels of p21(Waf1/Cip1), gelsolin, Ac-histone 4, and Ac-tubulin markedly increased after treatment of cancer cells with NBM-HD-
1. After NBM-HD-1 treatment for 1–4h, p-PTEN and p-AKT levels were markedly decreased. Furthermore, we also found the
anticancer activities of NBM-HD-1 in regulating cell cycle regulators. Treatment with NBM-HD-1, p21(Waf1/Cip1) gene expression
had markedly increased while cyclin B1 and D1 gene expressions had markedly decreased. On the other hand, we found that NBM-
HD-1 increased the expressions of tumor-suppressor gene p53 in a dose-dependent manner. Finally, we showed that NBM-HD-1
exhibited potent antitumor activity in a xenograft model. In conclusion, this study demonstrated that this compound, NBM-HD-
1, is a novel and potent HDACi with anticancer activity in vitro and in vivo.
1.Introduction
Chromatin,adenselypackedhigher-ordercomplexstructure
containing DNA and proteins, is present in eukaryotic cells.
The functions of chromatin are to package DNA into a small
volume to ﬁt in eukaryotic cells and to serve as a mechanism
to control gene expression and DNA replication. Major com-
ponents of chromatin are negatively charged DNA or RNA
and other associated proteins especially histones. Histones
contain an octamer complex of two copies of H2A, H2B, H3,
andH4proteins,whichareverybasicbecauseofarichnessof
the positively charged amino acids such as Arg and Lys [1, 2].
Within nuclei of eukaryotic cells, regulation of gene expres-
sionoccursthroughadynamicprocessbetweentwodifferent
forms of heterochromatin and euchromatin [3, 4]. In gen-
eral, heterochromatin is highly compact and shuts down
or inactivates gene expression. In contrast, euchromatin is
loosely packed and is more accessible to RNA polymerases
in order to regulate gene expression. Posttranslational mod-
iﬁcations of chromatin, such as acetylation or deacetylation
at Lys residues, methylation at Lys or Arg residues, and phos-
phorylation at Ser resides, are important in gene regulation
[5]. All these chemical modiﬁcations of amino acids occur
on the N-terminal tail of histones [6].
Structural modiﬁcations of histones mainly occur via
acetylation or deacetylation of the N-terminal tail which
affects chromatin remodeling and modulation of gene ex-
pression [7, 8]. The states of acetylation and deacetylation of
histones are controlled by two diﬀerent types of enzymes [9]:
histone acetyltransferases (HATs) and histone deacetylases
(HDACs). HATs trigger a reaction that preferentially acet-
ylates speciﬁc Lys substrates (histones and nonhistone2 Evidence-Based Complementary and Alternative Medicine
proteins) to generate a relaxed form of chromatin, which
alters gene expressions. HDACs trigger an opposite reaction
by removing acetyl groups from Lys substrates to generate a
compact form of the chromatin structure [10]. In general,
high levels of acetylation of core histones induce highly
transcribed genes, and gene silencing was found to be highly
correlated with low levels of acetylation [11]. Many studies
demonstrated tumor-suppressor gene silencing in cancer
[12, 13], and this can be an important therapeutic cancer
target. HDAC inhibitors (HDACis) can block deacetyla-
tion reactions to maintain a state of high levels of acetylation
of core histones to activate silent genes such as p53,
p21(Waf1/Cip1), RB,p16,BRCA1,an dBRCA2[14–17]. Restor-
ing normal tumor-suppressor gene function is an important
strategy in cancer treatment [18]. HDACis can achieve this.
Inhibition of HDAC’s function can target certain speciﬁc
genes which result in cell-cycle arrest, and induce either
differentiation or apoptosis in several cancer cell lines [19–
22]. Other studies demonstrated that HDACis eﬃciently
inhibitedtumorgrowthinhumanxenograftmodelsandmay
be developed as novel anticancer agents [23, 24].
Mammalian HDACs are divided into four classes based
ontheirfunctionandstructuralhomologiestoyeastHDACs.
Rpd3 (class I), Hda1 (class II), Sir2 (class III), and class IV
are atypical categories [25]. Class I HDACs include HDAC-1,
-2, -3, and -8. Class II HDACs are able to shuttle between
the nucleus and cytoplasm, include HDAC-4, -5, -6, -7,
-9, and -10. HDAC-6 is a very important enzyme that
aﬀects cytoskeletal regulation, cell migration, and cell-cell
interactions. It can also regulate several biological processes
[26]. To design potent anticancer drugs, one needs to focus
on inhibiting class I HDACs, because they are found in the
nucleus, aﬀect the tertiary chromatin structure, and alter
many gene expressions involved in cancer-cell proliferation,
diﬀerentiation, and apoptosis [27]. HDACs are implicated
in cancer not only for modulating histones but also nonhi-
stone proteins. First, modiﬁcations of histone proteins are
implicated in epigenetics that may lead to cancers. Secondly,
nonhistone proteins (such as p53, α-tubulin, HIF-1α,a n d
HSP90) are also implicated in several oncogenic pathways.
HDACis were found to produce few side eﬀects in patients
and to have a high capacity for anticancer activities [28].
Therefore, HDACis are categorized as targeted anticancer
drugs. Currently, many potent pan-HDACis (nonspeciﬁc
HDACis) have been identiﬁed and are in clinical trials, such
as SAHA, MS-275, LAQ-824, FK-228, PXD-101, valproic
acid, and sodium phenylbutyrate [29].
Propolis, a natural resinous product, is collected from
various plant sources by honeybees, which use it to seal holes
in their honeycombs. It is one of the world’s most popular
functional foods. Ten propolins (propolins A–J) of the active
components were isolated and characterized from Taiwanese
green propolis (TGP) by our laboratory. Propolins were
shown to be powerful antioxidants with anticancer proper-
ties. Propolin G was isolated as a seventh compound from
TGP [30], and it was found to induce apoptotic eﬀects via
activation of caspases in two diﬀerent types of brain cancer
cell lines. This study used propolin G as a starting material
via semisynthesis to develop a novel and potent HDACi and
evaluated its anticancer activities in vitro and in vivo.
2.MaterialsandMethods
2.1. Cell Culture and Cell Number Determination. Human
MCF-7 breast cancer, rat C6 glioma cells were purchased
from the Food Industry Research and Development Institute
(Hsinchu, Taiwan). All cell lines were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Gibco, Grand Island,
NY, USA) containing 10% fetal bovine serum (FBS), a 1%
dilution of penicillin-streptomycin, and 2mM glutamine.
Cellsweremaintainedat37◦Cinahumidiﬁedatmosphereof
95% air and 5% CO2. Human MDA-MB-231 breast cancer
cells were also purchased from the Food Industry Research
and Development Institute (Hsinchu, Taiwan). Cells were
cultured in L-15 medium (Gibco, Grand Island, NY, USA)
containing 10% FBS, a 1% dilution of penicillin-streptomy-
cin, and 2mM glutamine. Cells were maintained at 37◦Ci n
a humidiﬁed atmosphere of 100% air. Cells were maintained
at 37◦C in a humidiﬁed atmosphere of 95% air and 5% CO2.
NBM-HD-1 was dissolved in DMSO (dimethyl sulfoxide)
and prepared at a ﬁxed concentration of 10mg/mL. Cells
(1.0 × 106 per dish) were cultured in a 100mm dish and
incubated for 14h before treatment with DMSO or with
various concentrations of NBM-HD-1 (2.5, 5.0, 7.5, and
10.0μg/mL) for diﬀerent times. NBM-HD-1 is a small com-
pound (MW 584Da). When these values were converted to
molarities, they were 4.3, 8.5, 12.8, and 17.0μM, respectively.
All of these treatments used various doses of NBM-HD-
1. The vehicle (DMSO) in the cell culture medium was at
a ﬁxed concentration of 2μL/mL. Cells were counted and
determined by a trypan blue exclusion assay.
2.2. Primary Astrocytes. R a ta s t r o c y t e sw e r ep r e p a r e df r o m
the cerebral cortexes of 17-day-old embryonic rats. The rat
cerebral cortex was dissected and incubated with trypsin at
roomtemperaturefor5min.Braincortexcellswerethenme-
chanically dissociated with a ﬁre-narrowed Pasteur pipette in
theculturemediumandplatedatadensity of2×106 cells for
10mL culture medium in a 100mm dish. Brain cortex cells
were cultured in DMEM containing 10% FBS, a 1% dilution
of penicillin-streptomycin solution, and 2mM glutamine for
6 days. Brain cortex cells were rapidly proliferated. Ninety-
ﬁve percent of the brain cortex cells were differentiation
into astrocytes and expressed GFAP (glial ﬁbrillary acidic
protein). GFAP is an intermediate ﬁlament protein that was
through to be speciﬁc biomarker for astrocytes in CNS
(centralnervous system).Astrocytes (3.0×105 perwell)were
seeded in 6-well plates and incubated for 14h then treated
with NBM-HD-1 at various concentrations for 48h for PCR
assay.
2.3. Total HDACs Enzymatic Activity Assay. Total HDACs
enzymeactivitywasdeterminedusingtheBoc-Lys(Ac)-AMC
ﬂuorometric HDAC activity assay kit (BioVision, Mountain
View, CA, USA). C6 cells were treated with NBM-HD-1 and
sodium butyrate (SB; Sigma, St. Louis, MO, USA) for 48h.Evidence-Based Complementary and Alternative Medicine 3
Cells were then collected and nuclear fractions were isolated
using a NucBuster extraction kit (71183-3; Novagen, San
Diego,CA,USA).Equalamountsofnuclearfractionproteins
(30.0μg) were analyzed using a Fluorometric HDAC Activity
Assay Kit (k330-100; BioVision). The ﬂuorescence intensity
was measured using a ﬂuorometric reader with excitation at
360nm and emission at 460nm.
2.4. Confocal Microscopy. MCF-7 cells were cultured on six-
well culture plates (3.0 × 105/well) and treated with NBM-
HD-1 at a ﬁxed concentration of 17.0μM, 4.0mM SB, or
with SAHA (Alexis Biochemicals, Plymouth Meeting, PA,
USA)asapositivecontrolat5.0μMfor24h.Aftertreatment,
cells were ﬁxed with methanol (80%) for 30min, washed
with phosphate-buﬀered saline (PBS), then treated with
Triton X-100 (0.3%, v/v) for 5min, and washed with PBS.
Cells were blocked with 5% bovine serum albumin (BSA) for
1h and washed with PBS, and then the speciﬁc antibodies
of anti-Ac-histone 3 (1:1000) or antigelsolin (1:1000)
were added overnight. Cells were washed and 2  antibodies
(1:1000; anti-mouse immunoglobulin G- (IgG-)FITC or
anti-rabbitIgG-TRITC)wereaddedfor1h.Themorphology
of nuclear chromatin was deﬁned by analysis of the DNA-
bindingdye,DAPI(1.0mg/mL,5μL),andproteinexpression
(gelsolin and Ac-histone 3) levels using a confocal imager
(BD, Franklin Lakes, NJ, USA).
2.5. Western Blot Assay. C6 and MCF-7 cells (1.0 × 106)o n
100mm dishes were treated with 17.0μM NBM-HD-1 for
varioustimes.Aftertreatment,cellswerecollectedandresus-
pended in 60μLl y s i sb u ﬀer (RIPA lysis buﬀer, Millipore,
Temecula, CA, USA). Equal amounts of proteins (30.0μg)
were mixed with 2x sample buﬀer, then resolved by 12.5%
SDS-PAGE and electrotransferred to a PVDF membrane
(Millipore, Bedford, MA, USA). Equivalent protein loading
was veriﬁed by staining the membrane with the reversible
dye, amido black (Sigma). This was followed by overnight
blocking with a solution composed of 20mM Tris-HCl (pH
7.4), 125mM NaCl, 0.2% Tween 20, and 3% BSA. Speciﬁc
antibodies used were anti-Ac-tubulin, antigelsolin, β-actin
(1:1000 of mouse monoclonal antibodies; Sigma), anti-Ac-
histone 4 (1:1000 of rabbit polyclonal antibodies; Upstate),
anti-PTEN, anti-phospho-PTEN, and anti-phospho-AKT
(1:1000 dilution of rabbitpolyclonal antibodies; Cell Signal-
ing Technology). Proteins were detected by enhanced chem-
iluminescence (ECL; Amersham Pharmacia Biotech, Amer-
sham, UK).
2.6. Gene Expression Analysis. Total RNAs were isolated from
C6 cells and rat astrocytes. Cells (3.0 × 105 per well) were
seeded in 6-well plates and incubated for 14h then treated
with NBM-HD-1 at various concentrations for 48h. Cells
were lysed, and the total RNA was extracted with an RNeasy
Mini kit (Qiagen, Valencia, CA, USA). Complementary
(c)DNA was prepared by a First Strand cDNA Synthesis Kit
(Toyobo, Osaka, Japan). A multiplex PCR was performed
(using the primers that are described in Supplementary
Table S1 in Supplementary Material available online at
doi:10.1155/2012/781417). After an initial denaturation at
95◦C for 1s, 30 cycles were performed at 95◦C for 30s, 52◦C
for 30s, and 72◦C for 60s. The last cycle was followed by a
5min extension at 72◦C.
2.7. Analysis of the Cell Cycle. C6 and MCF-7 cells (1.0 ×
106/dish) in a 100mm dish were treated with various
concentrations (4.3∼17.0μM) of NBM-HD-1 for 48h. Cells
were trypsinized and collected with ice-cold PBS. Cells were
r e s u s p e n d e di n2 0 0 μL PBS and ﬁxed by adding 800μL
of iced 100% ethanol then incubated overnight at −20◦C.
Cell pellets were collected by centrifugation, resuspended
in 1mL of hypotonic buﬀer (0.5% Triton X-100 in PBS
and 1.0μg/mL RNase A), and incubated at 37◦C for 30min.
Then, 1mL of PI solution (50.0μg/mL) was added, and the
mixture was allowed to stand at 4◦C for 30min. The cellular
DNA content was then analyzed by FACScan cytometry
(Becton Dickinson).
2.8. Xenograft Model Assay. Female BALB/c nude mice (5
weeks old) were injected subcutaneously (5.0 × 106 cells/
100μL/mice) with MDA-MB-231 cells. After 2-3 weeks of
treatment, approximately 50mm3 tumors were apparent in
all mice. Animals were then allocated at random to one of
three groups (n = 4). Three groups of nude mice were
treated with NBM-HD-1 at 50 and 100mg/kg/day (through
an intraperitoneal injection) respectively, and vehicle control
groupwastreatedwithDMSO/cremophor .Miceweretreated
every day for 35 days with NBM-HD-1 or the control
vehicle. The tumor weight was calculated after the mice were
sacriﬁced.
2.9. Statistical Analysis. Animal test and antiproliferation
assay results are presented as the mean ± SD. Student’s t-test
was used to calculate the statistical signiﬁcance of diﬀerences
between each group and the control group. Diﬀerences were
considered statistically signiﬁcant if P<0.05.
3. Results
3.1. Semisynthesis of NBM-HD-1. Propolin G (Figure 1(a))
was isolated through repeated chromatographic runs of the
95% ethanol extract of propolis glue under guidance of brain
cancer cell-growth inhibition. Final puriﬁcation of the active
fraction was achieved by HPLC on an RP column. The total
content of the active component, propolin G, was roughly
10–12% of the TGP glue [30]. Our previous study suggested
that propolin G induced growth inhibition and apoptosis
of a brain cancer cell line possibly due to modulation of
the expressions of cell cycle-regulator genes and further acti-
vation of caspases and mitochondrial pathways, ultimately
resulting in the induction of apoptosis in the brain cancer
cell lines [30]. Furthermore, we also found that propolin G
possesses a weak HDACi property. For this reason, we were
interested in the development of a more-potent HDACi from
propolin G. Several novel compounds were synthesized and
tested (Figure 1(a)). We found that NBM-HD-1 was a very
active compound that could inhibit cancer cell growth, due
to its potential as an HDACi.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: NBM-HD-1 inhibition of cancer cells growth. (a) Structures of propolin G, NBM-HD-1-1, NBM-HD-1-2, and NBM-HD-1. (b)
Cells growth inhibition of NBM-HD-1 after treatment with various concentrations in rat C6 glioma cells, human MCF-7 breast cancer cells,
and human MDA-MB-231 breast cancer cells for 48h. (c) Human MDA-MB-231 breast cancer cells (3.0 × 105 per well) were cultured in
6-well plates and incubated for 14h, then treated with a ﬁxed concentration of 17.0μM for 1–3 days. Data are shown as the mean ± SD.
∗∗P<0.01; ∗∗∗P<0.001 versus the control. All these tests were performed in three independent experiments. A representative experiment
of the three replicates is shown.
3.2. Inhibition of Cell Growth by NBM-HD-1. C6, MCF-7,
and MDA-MB-231 cells were treated with NBM-HD-1 at
variousconcentrationsof4.3–17.0μMfor48h(Figure 1(b)).
These three cancer cell lines were sensitive to NBM-HD-1,
with IC50 values of 8.5–10.3μM( Table 1).
Furthermore, we also evaluated the eﬀect of NBM-HD-
1 treatment in various human cancer cell lines including
human Hs683 glioma cells, human HT-29 colon cancer cells,
and human DBTRG-05MG glioblastoma cancer cells and
human Hs68 ﬁbroblast cells (Table 1). All of these cell linesEvidence-Based Complementary and Alternative Medicine 5
exhibited similar results to those of C6 and MCF-7 or MDA-
MB-231 cells. MCF-7, C6, and HT-29 cells were found to
be more sensitive than other cancer cell lines. The normal
cell line of Hs68 cells was more resistant than other cancer
celllines.TheseresultssuggestedthatNBM-HD-1isselective
for inhibition of diﬀerent types of cell growth. On the other
hand, we also evaluated the inhibition of cell growth activity
aftertreatmentofMDA-MB-231cellswithaﬁxedconcentra-
tion of 17.0μM NBM-HD-1 for 24, 48, and 72h as shown in
Figure 1(c). NBM-HD-1 signiﬁcantly suppressed MDA-MB-
231 cell growth in a time-dependent manner. These results
demonstrated that NBM-HD-1 possesses the ability to
inhibit cancer cell growth. Furthermore, comparison with
three diﬀerent series of analogs of methylated-propolin
G (NBM-HD-1-1), hydrated-propolin G (NBM-HD-1-2),
and methylated-hydrated-propolin G (NBM-HD-1) was
also evaluated for inhibition of the cell-growth capacity
(Figure 1(a)). This result demonstrates that methylation or
hydration of propolin G alone does not possess excellent
activity for cell growth inhibition (data not shown). NBM-
HD-1 was derived from propolin G via the two processes
of methylation and hydration (Supplementary Material). On
the other hand, we also evaluated NBM-HD-1 and propolin
G in MDA-MB-231 cells. Treatment with equal concentra-
tion (17.0μM) of compounds, NBM-HD-1 inhibited cell
growth and induced diﬀerentiation. However, propolin G
induced cytotoxicity (data not shown). Taken together, these
results suggest that both methylation and hydration are re-
quired to obtain an active compound and might be a potent
diﬀerentiation inducer.
3.3. NBM-HD-1 Is an Inhibitor of HDAC. Using a trypan
blue exclusion assay to evaluate cell growth inhibition, we
found that NBM-HD-1 signiﬁcantly inhibited cell growth
but not induced cytotoxic eﬀect to those cancer cell lines.
Inhibition of cell proliferation was clearly present in NBM-
HD-1-treated cells (Table 1 and Figures 1(b) and 1(c)). To
determine whether NBM-HD-1 is an inhibitor of HDAC, C6
cells were treated with various concentrations of NBM-HD-
1 for 48h and then nuclear-fraction proteins were isolated
to determine the inhibition of HDAC enzyme activity.
As shown in Figure 2(a), NBM-HD-1 markedly inhibited
nuclear HDACs enzyme activity compared to SB (sodium
butyrate, a noted HDACi as a positive control). This result
suggests that NBM-HD-1 may be an HDACi. As shown in
Figures 2(b) and 2(c), both compounds (SB and SAHA)
signiﬁcantly upregulated Ac-histone 3 and gelsolin protein
expressions. Similarly, we also found that NBM-HD-1 sig-
niﬁcantly increased expression of both proteins (Ac-histone
3 and gelsolin). These results suggest that NBM-HD-1 is an
HDACi.
3.4. Upregulation of Ac-Histone 4 Levels by NBM-HD-1.
Next, we examined whether NBM-HD-1 inhibited cell
growth through inhibition of HDACs activity in C6 and
MCF-7cells.Forthis,weusedawesternblotassaytoevaluate
whether NBM-HD-1 caused suppression of cell growth
throughinhibitionofHDACsactivity.Cellsweretreatedwith
Table 1: Inhibition of cancer cell lines by NBM-HD-1. Cells were
incubated with NBM-HD-1 for 3 days.
Cell lines IC50 (μM)
MCF-7 8.5
C6 8.7
MDA-MB-231 10.3
Hs683 12.7
HT-29 9.4
DBTRG-05MG 12.3
Hs68 (normal cell line) 25.0
NBM-HD-1 (17.0μM)or SB (4.0mM) and Ac-histone 4 lev-
els signiﬁcantly increased compared to the untreated group.
In this experiment, cells were treated with individual com-
pounds for 2h as above, then the compounds were removed,
and cells were incubated without the drug for another 6h
(SB) or 2, 4, and 6h (NBM-HD-1). As shown in Figures 3(a)
and3(b),SB-inducedAc-histone4proteinlevelssigniﬁcantly
decreased 6h after removal of SB. In comparison, the decline
in Ac-histone 4 protein levels induced by NBM-HD-1 was
slower than those induced by SB. Because SB is a very polar
compound and can easily dissolve in water, it could very
easily be removed from the culture medium. However, the
polarity of NBM-HD-1 is less than SB, hence, the water
solubility of NBM-HD-1 is relatively less than SB. We as-
sumed that it could easily pass through cell membranes and
enter the nucleus. Therefore, after removing NBM-HD-1
from the culture media, cells were still being acted on by
NBM-HD-1.
3.5. Eﬀects of NBM-HD-1 on Cell-Cycle Regulators. Recently,
a study demonstrated that the D1 cyclin and cyclin-
dependent kinase inhibitor, p21(Waf1/Cip1),i sa ni m p o r t a n t
regulator of the cell cycle in breast cancer [31]. Many studies
also demonstrated that cell-growth inhibition is regulated by
cell-cycle regulators, including the cyclin-dependent kinase
inhibitor, p21(Waf1/Cip1), and cyclins B1, D1, and E [32–34].
We investigated the inhibitory eﬀect of NBM-HD-1 on C6
cells growth. Using an RT-PCR, we studied gene expressions
of these cell-cycle regulators in C6 cells after treatment with
NBM-HD-1 at various concentrations (4.3–21.5μM) for
48h. In each case, multiple gene analyses with GAPDH
were used to standardize mRNA levels over the course of
the experiment. p21(Waf1/Cip1) gene expressions markedly
increasedaftertreatmentwithNBM-HD-1atconcentrations
of 12.8–21.5μM; while cyclin B1 and D1 gene expressions
markedly decreased after treatment with NBM-HD-1 at con-
centrations of 12.8–21.5μM as shown in Figure 4(a). Several
studies demonstrated an association of cancer progression
and cell-cycle regulation. Based on these ﬁndings, cell-cycle
regulation has become a target for controlling cancers [35,
36]. p21(Waf1/Cip1) is a very important cell-cycle regulator
and tumor-suppressor gene. Next, we used ﬂow cytometry
to evaluate whether NBM-HD-1-caused cell growth sup-
pression is via regulated cell cycle. C6 and MCF-7 cells were
treated with NBM-HD-1 (0–17.0μM) for 48h for the cell6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Determination of the inhibition of total HDAC activity by NBM-HD-1. (a) C6 cells (6.0 × 105) were seeded in 60mm dishes and
incubated for 14h then treated with various concentrations (4.3–17.0μM) of NBM-HD-1 and SB (4.0mM, as a positive control) for 48h,
and then the nuclear fraction protein was isolated to determine the inhibition of total HDAC enzyme activity. Data are shown as the mean
± SD. ∗P<0.05; ∗∗∗P<0.001 versus the control. C6 and MCF-7 cells were cultured in six-well culture plates (3.0 × 105/well) and treated
with NBM-HD-1 (at a ﬁxed concentration of 17.0μM), SAHA (5.0μM), or SB (4.0mM) for 24h. Immunostaining was used to evaluate
biomarkers of HDACis such as Ac-histone 3 and gelsolin after cells were treated with HDACis. (b) Ac-histone 3 and (c) gelsolin protein levels
were determined by confocal microscopy. All these tests were performed in three independent experiments. A representative experiment of
the three replicates is shown.
cycle analysis. Our result indicates no signiﬁcantly increased
apoptotic cell population (sub-G1 phase) following NBM-
HD-1(0–17.0μM)treatment(Figure 4(b)).However,thecell
population at the G0/G1 phase was signiﬁcantly increased
in a dose-dependent manner as shown in Figure 4(b). Taken
together, we think that p21(Waf1/Cip1) gene overexpression
may be increased the cell population at the G0/G1 phase
after treatment with NBM-HD-1.
3.6. Upregulation of Tumor-Suppressor Gene by NBM-HD-1.
Rat primary astrocytes were normal brain cells in CNS. Cells
were treated with NBM-HD-1 at various concentrations (0∼
17.0μM) for 48h. An RT-PCR was used to measure the
tumor-suppressor gene expression. As shown in Figure 4(c),
p53 gene expressions were signiﬁcantly upregulated after
treatment with NBM-HD-1 compared to SB (4.0mM). This
resultdemonstratesthatNBM-HD-1mayhavehadthecapa-
bility to restore or awaken tumor-suppressor genes. HDACis
arethoughttobecapableofwakingupsilencedexpressionof
tumor-suppressor genes [37]. Our results suggest that NBM-
HD-1 may be useful in controlling cancer-cell proliferation
and maintaining or upregulating the function of tumor-
suppressor genes in normal cells.
3.7. NBM-HD-1 Inhibits HDAC Enzymatic Activity, Also
SuppressesthePhosphorylationofPTENandAKT. Thisstudy
also explored the anticancer mechanisms of NBM-HD-1.
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β-actin
Ac-histone 4
0 2 6 1 2 2 4 6 (h)
SB (4mM) NBM-HD-1 (17μM)
1 5.2 3.6 0.3 2.1 3.8 3.5 3.6
Add Remove Remove
Relative intensity
(a)
β-actin
Ac-histone 4
026 1 2 2 4 6 (h)
SB (4mM) NBM-HD-1 (17μM)
1 4.5 2.1 0.2 4.8 6.2 4.6 4.5
Add Remove Remove
Relative intensity
(b)
Figure 3: Upregulation of Ac-histone 4 protein expressions after
treatment with NBM-HD-1 in various cancer cell lines. (a) C6 cells,
and (b) MCF-7 cells were treated with NBM-HD-1 (17.0μM) or SB
(4.0mM)for1-2horcellsweretreatedwiththesameconcentration
of both compounds for 2h, then the compound was removed, and
cells were incubated for another 2, 4, and 6h. Cell lysates were
prepared and subjected to SDS-PAGE and immunoblotting using
an Ac-histone 4 antibody.
AKT is the downstream target of PI3K in controlling angiog-
enesis and tumor growth. It can regulate many cell functions
such as proliferation, transformation, apoptosis, tumor
growth, and angiogenesis. Therefore, controlling the PTEN
or AKT signal pathway may be an important anticancer
mechanism. Cells were treated with NBM-HD-1 at a ﬁxed
concentration of 17.0μM for 1, 2, 3, and 4h. As shown
in Figure 5(a), protein levels of Ac-histones 4 markedly
increased after treatment for 2–4h. Similar result was also
seen with Ac-tubulin protein as shown in Figure 5(b). These
results demonstrate that NBM-HD-1 may be able to rapidly
move into cell membranes and the nucleus to regulate chro-
m a t i nr e m o d e l i n ga n da ﬀect gene and protein expressions.
We also found that NBM-HD-1 suppressed phospho-PTEN
expression after treatment for 2h (Figure 5(c)). A similar
result was also found for the phospho-AKT protein as shown
in Figure 5(c). Neither PTEN nor AKT expression markedly
changed after treatment with NBM-HD-1. Taken together,
our data suggest that NBM-HD-1 not only inhibits HDAC
enzyme activity but also downregulates PTEN and AKT
phosphorylation.
3.8. NBM-HD-1 Inhibits Tumor Growth in Mice. NBM-HD-
1 was injected intraperitoneally (i.p.) into immunodeﬁcient
mice once daily for 35 days. As shown in Figure 6(a), the
tumorsizesigniﬁcantlydecreasedaftertreatmentwithNBM-
HD-1 (100mg/kg/day). Furthermore, tumor weights were
calculated and analyzed by Student’s t-test as shown in
Figure 6(b). The body weight of mice did not signiﬁcantly
change after treatment with NBM-HD-1 (data not shown).
The activity of NBM-HD-1 in this MDA-MB-231 cells
xenograft model suggests that it may be a good lead com-
pound for developing novel HDACi for targeted cancer
therapy.
4. Discussion
In the present study, we have described a novel type of
HDACiwithpotentantiproliferativeactivityinseveralcancer
cell lines (Table 1). We also showed that an i.p. injection of
NBM-HD-1 exhibited antitumor activity in an MDA-MB-
231 breast cancer xenograft model (Figure 6). Currently, sev-
eral HDACis that have come up with predictable treatment
for hematological malignancies are still in developmental
stage [20, 38]. The US Food and Drug Administration
approved SAHA (vorinostat) and FK-228 (romidepsin) for
treating cutaneous T-cell lymphoma (CTCL) in 2006 and
2009, respectively. However, HDACis activity in solid tumors
has been limited [39]. The reason why HDACi activity in
solid tumors is weak compared to hematological malignan-
cies may be its correlation with the inhibition classes of
HDACs by HDACi with diﬀerent cancer cells.
SAHA is one of the most promising pan-HDACi which
can potently inhibit several HDACs such as HDAC-1, -2, -3,
-6, -8, and -10 in the nanomolar range [40]. In particular,
SAHA inhibits class I HDACs (HDAC-1, -2, and -3), re-
sulting in the acetylation of nuclear histone proteins which
aﬀects the chromatin structure. Finally, SAHA inﬂuences
the expressions of many genes involved in cancer-cell pro-
liferation, apoptosis, and diﬀerentiation. However, one study
demonstrated that HDACi’s inhibition of HDAC-1 may trig-
ger neurotoxicity [41]. In our laboratory, we found that a
low dose of about 1.0μM of SAHA had strong neurotoxicity
on rat cortical neurons and neural stem cells, but this phe-
nomenon did not exist by treatment with NBM-HD-1 (data
not shown). These results support the current trend towards
developing speciﬁc HDACis for targeted cancer therapy with
reduced side eﬀects.
Propolin G is a natural product isolated and charac-
terized from TGP. Previously, we showed that propolin G
possesses a strong capacity to induce apoptosis in brain
cancer cells [30]. We also found that it can pass the blood-
brain barrier (BBB, data not shown). However, developing
potent HDACis with few side eﬀects is very important for the
acceptance of these agents for targeting therapeutic drugs.
For this reason, NBM-HD-1 was derived through a two-
step semisynthesis process. Several NBM-HD-1 analogs were
generated and tested in antiproliferation assays in several
cancer cell lines. Among them, NBM-HD-1 had an excellent
capacity to inhibit cell growth. The result suggests that both
hydration positions at geranyl and isoprenyl side chains are
required to obtain an active compound. Furthermore, meth-
ylation of these compounds are also required for anticancer
activity. Compare to our previous study [42], we demon-
strated that either three methoxy groups (3 ,4 ,7-trimethox-
yﬂavanone, NBM-HD-3) or four methoxy groups (3 ,4 ,5,7-
tetramethoxyﬂavanone, NBM-HD-1) exhibited highly inhi-
bition activity of HDACs. We use diﬀerent methods to
synthesis these two compounds while both of them are8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Regulation of cell cycle-regulator and tumor suppressor genes in NBM-HD-1-treated cells. (a) C6 cells (3.0 × 105 per well) were
seededin6-wellplatesandincubatedfor14hthentreatedwithNBM-HD-1atvariousconcentrations(4.3∼21.5μM)for48h.p21(Waf1/Cip1),
cyclin B1,a n dcyclin D1 cell cycle-regulator genes were determined by RT-PCR. (b) Flow cytometric analysis of NBM-HD-1-treated C6 and
MCF-7 cells for 48h and stained with PI. Following the ﬂow cytometric analysis, the cellular DNA proﬁle was analyzed by Cell Quest
software. Rat astrocytes (3.0 × 105 per well) were seeded in 6-well plates and incubated for 14h then treated with NBM-HD-1 at various
concentrations (4.3–17.0μM) and 4.0mM of SB for 48h. (c) p53 tumor-suppressor genes were determined by RT-PCR. All these tests were
performed in three independent experiments. A representative experiment of the three replicates is shown.
derivedfromTaiwanesegreenpropolis. Actually,somemajor
diﬀerences existed among these two compounds. First,
NBM-HD-3 is eﬀective for antiproliferation on the brain
tumor cells [42]; however, NBM-HD-1 is more pronounced
in targeting human breast cancer cells as shown in Table 1
and Figure 6. For example, in MCF-7 human breast cancer
cells, the IC50 in NBM-HD-3 is 40% higher than NBM-
HD-1. On the contrary, in Hs683 human brain cancer cells,
NBM-HD-1 is almost half potency compared to NBM-HD-
3. Second, the translation regulation of PTEN and AKTEvidence-Based Complementary and Alternative Medicine 9
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Figure 5:NBM-HD-1inhibitscellgrowththroughaPTEN/AKT-dependentpathway.MCF-7cells(1.0×106)wereseededin100mmdishes,
incubated for 14h, and then treated with NBM-HD-1 at a ﬁxed concentration of 17.0μM for 1, 2, 3, and 4h. Cell lysates were prepared and
subjected to SDS-PAGE and immunoblotting using respective speciﬁc antibodies. (a) Ac-histones 4. (b) Ac-tubulin. (c) Phospho-PTEN and
phospho-AKT. HDACi biomarkers were determined by a western blot assay.
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Figure 6: NBM-HD-1 inhibits tumor growth in vivo after intraperitoneal (i.p.) administration. Nude mice were injected subcutaneously
with MDA-MB-231 cells (5.0 × 106 per mouse). NBM-HD-1 was i.p. injected daily for 35 days. (a) The surgical tumors. (b) Tumor weights
were measured after the mice were sacriﬁced. Student’s t-test was used to calculate the statistical signiﬁcance of diﬀerences between each
group and the control group. Data are shown as the mean ± SD. ∗∗P<0.01 versus the control.
proteins by these two compounds is quite diﬀerent. After
treatment with NBM-HD-3, the expression of either PTEN
orAKTproteins areelevatedsigniﬁcantly[42],butnotinthe
cells that treatment with NBM-HD-1 (Figure 5(c)). Third, it
has been demonstrated that the ﬂavonoids with 5-methoxy
group has lower antioxidant activities then those with 5-
hydroxy group and showed relatively low IC50 to cancer
cells [43]. This may indicate that the compound NBM-HD-1
may exhibited relatively low antioxidant activity compared
with NBM-HD-3. However, the results we observed from
thesetwosemisyntheticcompoundsshowedthattheeﬀective
antitumor ability is provided with NBM-HD-1 and NBM-
HD-3 against breast cancer and brain cancer, respectively.
On the other hand, several classes of HDACis were deﬁned
[44], including (a) short-chain fatty acids (SB, sodium
phenylbutyrate, and valproic acid); (b) cyclic tetrapeptides
(trapoxin,FK-228,andapicidin);(c)hydroxamicacids(TSA,
SAHA, and LAQ-824); (d) benzamides (MS-275). NBM-
HD-1 could not be classiﬁed into any of these four classes.
Therefore, it is a novel type of HDACi.
From the western blot data, we found that NBM-HD-1
h a da ne ﬀect on cancer cells within a short period after treat-
ment with a ﬁxed concentration of 17.0μMa t1 – 4 ha s
shown in Figure 5. Ac-histone 4 protein levels markedly
increased suggesting that NBM-HD-1 might aﬀect HDAC-3
and increase Ac-histone 4 expressions in nuclei of cancer
cells. Ac-tubulin signiﬁcantly increased after treatment with
NBM-HD-1. This result suggests that NBM-HD-1 can aﬀect
HDAC-6. Interestingly, phosphorylations of PTEN and
AKT were markedly downregulated after treatment with10 Evidence-Based Complementary and Alternative Medicine
NBM-HD-1. This result suggests that NBM-HD-1’s inhi-
bition of cancer-cell growth may be via downregulation of
the PTEN/AKT signal pathway. Based on these ﬁndings, we
speculated that the PTEN/AKT pathway is involved in NBM-
HD-1’s induction of cancer-cell growth inhibition in MCF-7
cells. Taken together, our data suggest that NBM-HD-1 not
only inhibits HDACs enzyme activity but also suppresses the
PTEN/AKT pathway in cancer cells.
Concluding this study, we obtained a novel HDACi,
called NBM-HD-1, derived from propolin G using two sim-
ple steps (methylation and hydration, Supplementary Ma-
terial). Our data suggest that NBM-HD-1 may be a potent
HDACiwhichsuppressescancer-cellgrowthinseveralcancer
cell lines. This anticancer eﬀect did not occur through a
cytotoxic eﬀect (Figures 1(b) and 4(b)). Its anticancer mech-
anisms may involve two pathways. First, NBM-HD-1 inhib-
ited HDAC enzyme activity, aﬀecting chromatin core his-
tones and induced changes in gene expression to control
the cell cycle. Second, NBM-HD-1 suppressed the PTEN/
AKT pathway to inhibit cancer cell growth. These two factors
may be pertinent to the anticancer eﬀect of NBM-HD-1
treatment. Developing promising HDACis for treating solid
tumors is a diﬃcult problem. NBM-HD-1 seems to have the
potential to resolve this problem.
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